Download
s13014-021-01962-8.pdf 1,16MB
WeightNameValue
1000 Titel
  • Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy—GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study
1000 Autor/in
  1. König, Laila |
  2. Jäkel, Cornelia |
  3. von Knebel Doeberitz, Nikolaus |
  4. Kieser, Meinhard |
  5. Eberle, Fabian |
  6. Münter, Marc |
  7. Debus, Jürgen |
  8. Herfarth, Klaus |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-12-20
1000 Erschienen in
1000 Quellenangabe
  • 16(1):240
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13014-021-01962-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691033/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are often accompanied by increases in toxicity. By using proton beams instead of photon beams, it is possible to protect large parts of the brain which are not affected by the tumor more effectively. An initial retrospective matched-pair analysis showed that this theoretical physical benefit is also clinically associated with a reduction in toxicity during therapy and in the first few months thereafter.!##!Methods/design!#!The GRIPS trial is a multicenter, prospective, open-label, randomized, two-arm, phase III study using either intensity modulated photon radiation techniques (standard arm) or proton beam radiotherapy (experimental arm). Additionally, patients are stratified according to 'fractionation scheme' (normofractionated/hypofractionated), 'subventricular zone involvement' (yes/no) and concurrent chemotherapy (yes/no) and the planned case number is 326 patients. Radiation therapy is performed with a dose of 30 × 2 Gy(RBE) or 33 × 1.8 Gy(RBE), or for patients treated according to the hypofractionation protocol with 15 × 2.67 Gy(RBE). A possible administration of additional chemotherapy (concurrent or adjuvant) or tumor treating fields is applied in dosage and frequency according to the therapy standard outside of this study. The primary endpoint is the cumulative rate of toxicity CTC grade 2 and higher in the first 4 months. Secondary endpoints include overall survival, progression-free survival, quality of life, and neurocognition.!##!Discussion!#!Aim of the GRIPS study is to prospectively assess whether the theoretical physical advantage of proton beam radiotherapy will translate into a clinical reduction of toxicity during and in the first months after therapy. Trial registration ClinicalTrials (NCT): NCT04752280.
1000 Sacherschließung
lokal Brain Neoplasms/radiotherapy [MeSH]
lokal Chemoradiation
lokal Study Protocol
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Clinical Radiation Oncology
lokal Glioblastoma
lokal Randomized Controlled Trials as Topic [MeSH]
lokal Glioblastoma/radiotherapy [MeSH]
lokal Proton Therapy/methods [MeSH]
lokal Glioblastoma/mortality [MeSH]
lokal Brain Neoplasms/mortality [MeSH]
lokal RANO
lokal Toxicity
lokal Proton radiotherapy
lokal Radiotherapy Dosage [MeSH]
lokal Radiotherapy, Intensity-Modulated/methods [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-8402-6694|https://frl.publisso.de/adhoc/uri/SsOka2VsLCBDb3JuZWxpYQ==|https://frl.publisso.de/adhoc/uri/dm9uIEtuZWJlbCBEb2ViZXJpdHosIE5pa29sYXVz|https://frl.publisso.de/adhoc/uri/S2llc2VyLCBNZWluaGFyZA==|https://frl.publisso.de/adhoc/uri/RWJlcmxlLCBGYWJpYW4=|https://frl.publisso.de/adhoc/uri/TcO8bnRlciwgTWFyYw==|https://frl.publisso.de/adhoc/uri/RGVidXMsIErDvHJnZW4=|https://frl.publisso.de/adhoc/uri/SGVyZmFydGgsIEtsYXVz
1000 Hinweis
  • DeepGreen-ID: f8a7ee8b8a034fbab45765c897c5f828 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6443384.rdf
1000 Erstellt am 2023-04-26T18:32:34.533+0200
1000 Erstellt von 322
1000 beschreibt frl:6443384
1000 Zuletzt bearbeitet Thu Oct 19 14:36:39 CEST 2023
1000 Objekt bearb. Thu Oct 19 14:36:39 CEST 2023
1000 Vgl. frl:6443384
1000 Oai Id
  1. oai:frl.publisso.de:frl:6443384 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source